Company intelligence / Profile preview
Sintica Biotech
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Sintica Biotech has developed SNT001, a proprietary peptidomimetic targeting CD271 to induce apoptosis in melanoma cells. Preclinical studies have demonstrated promising anti-metastatic activity both in vitro and in vivo, aiming to address resistance seen with current therapies[2][8].
- Therapeutic areas
- Oncology
- Modalities
- PeptidomimeticSmall molecule (new chemical entity)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sintica Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sintica Biotech.